

1 **Impact of molecular weight on the formation of electrosprayed**
2 **chitosan microcapsules as delivery vehicles for bioactive compounds**

3

4 Laura G. Gómez-Mascaraque¹, Gloria Sanchez^{2,3}, Amparo López-Rubio^{1*}

5

6 ¹Food Quality and Preservation Department, IATA-CSIC, Avda. Agustín Escardino 7,
7 46980 Paterna, Valencia, Spain

8 ²Department of Microbiology and Ecology, University of Valencia, Valencia, Spain

9 ³Molecular Taxonomy Group, IATA-CSIC, Avda. Agustín Escardino 7, 46980 Paterna,
10 Valencia, Spain

11

12 *Corresponding author: Tel.: +34 963900022; fax: +34 963636301 (A. López-Rubio)

13 E-mail addresses: lggm@iata.csic.es (L. G. Gómez-Mascaraque),

14 gloriasanchez@iata.csic.es (G. Sanchez), amparo.lopez@iata.csic.es (A. López-Rubio)

15

1

16

¹ **Abbreviations:** ABTS, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt; DDA, degree of deacetylation DFA, Discriminant Function Analysis; EGCG, (-)-epigallocatechin gallate; FT-IR, Fourier transform infrared spectroscopy; GRAS, Generally Recognised As Safe; MEE, microencapsulation efficiency; MNV, murine norovirus; Mw, molecular weight(s); PBS, phosphate buffer saline; RSA, radical scavenging activity; SEM, scanning electron microscopy.

17 **Abstract**

18 The molecular weight of chitosan is one of its most determinant characteristics, which
19 affects its processability and its performance as a biomaterial. However, information
20 about the effect of this parameter on the formation of electrosprayed chitosan
21 microcapsules is scarce. In this work, the impact of chitosan molecular weight on its
22 electrosprayability was studied and correlated with its effect on the viscosity, surface
23 tension and electrical conductivity of solutions. A Discriminant Function Analysis
24 revealed that the morphology of the electrosprayed chitosan materials could be correctly
25 predicted using these three parameters for almost 85% of the samples. The suitability of
26 using electrosprayed chitosan capsules as carriers for bioactive agents was also assessed
27 by loading them with a model active compound, (–)-epigallocatechin gallate (EGCG).
28 This encapsulation, with an estimated efficiency of around 80% in terms of preserved
29 antioxidant activity, showed the potential to prolong the antiviral activity of EGCG
30 against murine norovirus via gradual bioactive release combined with its protection
31 against degradation in simulated physiological conditions.

32

33 **KEYWORDS**

34 Electrospray; chitosan; molecular weight; microencapsulation; catechin; antiviral

35 **1. Introduction**

36 Micro- and nanoencapsulation, processes in which a compound is embedded within a
37 protective matrix (Jiménez-Martín, Gharsallaoui, Pérez-Palacios, Carrascal & Rojas,
38 2014) which is organized in the form of micro- or nanosized structures, have attracted
39 increasing research interest for the protection of sensitive bioactive compounds (Pérez-
40 Masiá, López-Nicolás, Periago, Ros, Lagaron & López-Rubio, 2015) and address
41 current concerns related to their formulation, bioavailability or their delivery to specific
42 sites (Zaki, 2014).

43 Among the different techniques used for microencapsulation, electrohydrodynamic
44 spraying (electrospraying) is rapidly emerging as a promising technology for the
45 production of polymeric microparticles containing bioactive molecules (Bock,
46 Dargaville & Woodruff, 2012), as it overcomes some of the limitations of conventional
47 methods. Electrospraying can generate microencapsulation structures in a one-step
48 process (Chakraborty, Liao, Adler & Leong, 2009) under mild conditions (López-Rubio
49 & Lagaron, 2012; Sosnik, 2014) and in the absence of organic/toxic solvents (Tapia-
50 Hernández et al., 2015), limiting inactivation of the bioactive compounds (Zamani,
51 Prabhakaran & Ramakrishna, 2013), being adequate for both hydrophilic and
52 hydrophobic drugs or ingredients (Gómez-Mascaraque & López-Rubio, 2016) and
53 generally achieving high loading efficiencies (Sosnik, 2014; Zamani, Prabhakaran &
54 Ramakrishna, 2013). Therefore, it has found a number of potential applications in
55 various fields, including the pharmaceutical, cosmetic and food industries (Jaworek &
56 Sobczyk, 2008). It basically consists on subjecting a polymer solution (containing the
57 bioactive to be encapsulated) to a high voltage so that the electric field deforms the
58 interface of the liquid drop and breaks it into fine charged droplets, which are ejected

59 towards a collector while the solvent evaporates, generating dry polymeric
60 microparticles (Anu Bhushani & Anandharamakrishnan, 2014; Sosnik, 2014).

61 Biopolymers are preferred as encapsulating matrices for most applications because of
62 their biocompatibility, biodegradability and non-toxicity (Ghorani & Tucker, 2015).
63 Specially, chitosan is a biorenewable, biocompatible and biodegradable polysaccharide
64 considered a GRAS food additive by the FDA (Luo & Wang). Moreover, it has many
65 attributed functional and bioactive properties, including antioxidant and lipid-lowering
66 capacities, antimicrobial activity, wound healing and antiangiogenic effects, prevention
67 of renal failure, etc. (Luo & Wang; Park, Saravanakumar, Kim & Kwon, 2010; Ribeiro
68 et al., 2009). For these reasons chitosan and its derivatives have been widely used in the
69 pharmaceutical (Badwan, Rashid, Omari & Darras, 2015; Cheung, Ng, Wong & Chan,
70 2015), biomedical (Anitha et al., 2014; Ishihara, 2015), cosmetic (Anumansirikul, 2007;
71 Jimtaisong & Saewan, 2014) and food industries (Fathi, Martin & McClements, 2014;
72 Zivanovic, Davis & Golden, 2014), and is considered a good candidate for the
73 encapsulation of bioactive compounds (Estevinho, Rocha, Santos & Alves, 2013;
74 Varshosaz, 2007). However, the electrohydrodynamic processing of chitosan is
75 complex due to its particular behavior in solution and its polycationic nature
76 (Homayoni, Ravandi & Valizadeh, 2009), consequence of its structure consisting of β -
77 1,4 linked 2-acetamido-2-deoxy- β -D-glucopyranose units and 2-amino-2-deoxy- β -D-
78 glucopyranose units (cf. Figure S1 of the Supplementary Material) (Khor & Lim, 2003).

79 The electrohydrodynamic spinning (electrospinning) of chitosan for the production of
80 nanofibers from non-toxic solvents has been extensively studied (Sun & Li), and the
81 impact of different processing parameters, solution properties and/or the molecular
82 weight of the polymer on the morphology of the obtained fibers have been addressed
83 (Geng, Kwon & Jang, 2005; Homayoni, Ravandi & Valizadeh, 2009). However, as the

84 focus of these works is the manufacture of fibers, the range of explored conditions does
85 not cover the production of nano/microparticles. The use of electrospraying for the
86 production of dry (Arya, Chakraborty, Dube & Katti, 2009; Zhang & Kawakami, 2010)
87 or gelled (Pancholi, Ahras, Stride & Edirisinghe, 2009; Wang et al., 2015; Yunoki,
88 Tsuchiya, Fukui, Fujii & Maruyama, 2014) chitosan micro- and nanospheres has also
89 been reported, however, all these works use only one particular grade of chitosan, with a
90 fixed molecular weight. Given that the molecular weight of chitosan is one of its key
91 characteristics, which can affect not only its processability but also its performance as a
92 delivery vehicle (Arya, Chakraborty, Dube & Katti, 2009), the focus of this work was to
93 study the influence of the molecular weight on the sprayability of chitosan, and to assess
94 the suitability of selected electrosprayed capsules as delivery vehicles for a model
95 bioactive compound: (–)-epigallocatechin gallate (EGCG). EGCG is the most abundant
96 and bioactive compound in green tea (Barras et al., 2009) and possesses many attributed
97 health benefits (Singh, Shankar & Srivastava, 2011), including protective effects against
98 infections (Steinmann, Buer, Pietschmann & Steinmann, 2013), cardiovascular and
99 neurodegenerative diseases (Fu et al., 2011), inflammation and arthritis (Singh, Akhtar
100 & Haqqi, 2010) and cancer (Larsen & Dashwood, 2009, 2010). In the present work, its
101 antioxidant (Fu et al., 2011) and antiviral (Dhiman, 2011; Xiao, 2008) activities were
102 assessed before and after encapsulation within the chitosan electrosprayed capsules.

103

104 **2. Materials and Methods**

105 **2.1. Materials**

106 Chitosans with reported degree of deacetylation of 85 ± 2.5 % and different molecular
107 weights, ranging from 25 to 300 kDa, were purchased from Heppe Medical Chitosan

108 GmbH. (-)-Epigallocatechin gallate (EGCG), 2,2'-azino-bis(3-ethylbenzothiazoline-6-
109 sulfonic acid) diammonium salt (ABTS), potassium persulfate ($K_2O_8S_2$) and
110 spectroscopic grade potassium bromide (KBr) were obtained from Sigma-Aldrich. 96%
111 (v/v) acetic acid was supplied by Scharlab.

112

113 **2.2. Preparation of chitosan solutions**

114 Chitosan solutions of different concentrations, i.e. from 0.5 to 8 % (w/v), were prepared
115 by dissolving the polysaccharide in acetic acid at room temperature under magnetic
116 agitation overnight. Different acetic acid concentrations were used for this purpose,
117 from 20 to 90 % (v/v).

118

119 **2.3. Characterization of the solutions**

120 The surface tension of the solutions was measured using the Wilhemy plate
121 method in an EasyDyne K20 tensiometer (Krüss GmbH, Hamburg, Germany) at room
122 temperature.

123 The electrical conductivity of the solutions was measured using a conductivity meter
124 XS Con6 (Labbox, Barcelona, Spain) at room temperature.

125 The rheological behaviour of the solutions was studied using a rheometer model AR-G2
126 (TA Instruments, USA), with a parallel plate geometry, and the method described in
127 (Gómez-Mascaraque, Lagarón & López-Rubio, 2015). Briefly, continuous shear rate
128 ramps were performed from 0.1 to 200 s^{-1} during 15 min at 25 ± 0.1 °C using a stainless

129 steel plate with a diameter of 60 mm and a gap of 0.5 mm. All measurements were
130 made at least in triplicate.

131

132 **2.4. Electrohydrodynamic processing of the solutions**

133 The solutions were processed using a homemade electrospinning/electrospraying
134 apparatus, equipped with a variable high-voltage 0-30 kV power supply. Solutions
135 were introduced in a 5 mL syringe and were pumped at a steady flow-rate (0.15
136 mL/h) through a stainless-steel needle (0.9 mm of inner diameter). The needle was
137 connected through a PTFE wire to the syringe, which was placed on a digitally
138 controlled syringe pump. Processed samples were collected on a grounded stainless-
139 steel plate placed at a distance of 10 cm from the tip of the needle in a horizontal
140 configuration. A voltage of 17 kV was applied to the solutions as selected in
141 preliminary trials.

142

143 **2.5. Morphological characterization of the particles**

144 Scanning electron microscopy (SEM) was conducted on a Hitachi microscope (Hitachi
145 S-4800) at an accelerating voltage of 10 kV and a working distance of 7-10 mm. As
146 prepared samples were sputter-coated with a gold-palladium mixture under vacuum
147 prior to examination.

148

149 **2.6. Fourier transform infrared (FT-IR) analysis of the particles**

150 Samples (ca. 1-2 mg) of selected chitosan capsules, both unloaded and EGCG-loaded,
151 were grounded and dispersed in about 130 mg of spectroscopic grade potassium

152 bromide (KBr). A pellet was then formed by compressing the samples at ca. 150 MPa.
153 FT-IR spectra were collected in transmission mode using a Bruker (Rheinstetten,
154 Germany) FT-IR Tensor 37 equipment. The spectra were obtained by averaging 10
155 scans at 1 cm⁻¹ resolution.

156

157 **2.7. Antioxidant activity of free and encapsulated EGCG**

158 The ABTS^{•+} radical scavenging assay (Re, Pellegrini, Proteggente, Pannala, Yang &
159 Rice-Evans, 1999) was performed in order to quantify the antioxidant activity of both
160 free and encapsulated EGCG, following the protocol described in a previous work
161 (Gómez-Mascaraque, Lagarón & López-Rubio, 2015). Briefly, a stock solution of
162 ABTS^{•+} was prepared by reacting ABTS 7 mM with potassium persulfate 2.45 mM,
163 both in distilled water, and allowing the mixture to stand in the dark at room
164 temperature for 24 h. The stock solution was then diluted with acetic acid 20% v/v to an
165 absorbance at 734 nm of 0.70 ± 0.02. Solutions of free and encapsulated EGCG (0.15
166 mg/mL of EGCG in both cases) were prepared in acetic acid 20% v/v, and 10 µL
167 aliquots were added to 1 mL of diluted ABTS^{•+}, measuring its absorbance at 734 nm
168 after 1 min of mixing. The unloaded chitosan particles were also evaluated, at the same
169 polymer concentration as for the loaded samples. The radical scavenging activity
170 (RSA), expressed as the percentage of reduction of the absorbance at 734 nm after
171 sample addition, was calculated using Eq. (1), where A₀ and A₁ are the absorbances at
172 734 nm of ABTS^{•+} before and 1 min after addition of the samples, respectively.

173

$$174 \quad \text{RSA (\%)} = \frac{A_0 - A_1}{A_0} \times 100 \quad \text{Eq. (1)}$$

175

176 Experiments were performed on a V-1200 Spectrophotometer from VWR
177 (Pennsylvania, USA), at least in triplicate. Solvent blanks were also run in each assay.

178

179 **2.8. Microencapsulation efficiency**

180 The microencapsulation efficiency (MEE) of the EGCG-loaded capsules was estimated
181 from the value of their antioxidant activity according to Eq. (2), where both the free and
182 encapsulated EGCG had the same theoretical concentration in the solutions:

183

$$184 \quad MEE (\%) = \frac{RSA \text{ of EGCG-loaded capsules}}{RSA \text{ of free EGCG}} \times 100 \quad \text{Eq. (2)}$$

185

186 **2.9. Virus strain, cell line and infections**

187 The cytopathogenic murine norovirus (MNV-1) strain, a model for human noroviruses,
188 was propagated and assayed in RAW 264.7 (kindly provided by Prof. H. W. Virgin,
189 Washington University School of Medicine, USA) as described in Elizaquível,
190 Azizkhani, Aznar and Sánchez (2013). Semi-purified stocks were subsequently
191 produced from the same cells by centrifugation of infected cell lysates at 660×g for 30
192 min. Infectious viruses were enumerated by determining the 50% tissue culture
193 infectious dose (TCID₅₀) with eight wells per dilution and 20 µl of inoculum per well.

194

195 **2.10. Antiviral activity**

196 Different concentrations of free and encapsulated EGCG were added to MNV
197 suspensions (ca. 6 log TCID₅₀/mL) and further incubated at 37 °C in a water-bath

198 shaker at 150 rpm for 2 or 16 h (ON). Ten-fold dilutions of treated and untreated virus
199 suspensions were inoculated into confluent RAW monolayers in 96-well plates. Then,
200 infectious viruses were quantified by cell culture assays as described above. Each
201 treatment was done in triplicate. Positive controls were virus suspensions in PBS and
202 virus suspensions added to unloaded chitosan capsules. The decay of MNV was
203 calculated as $\log_{10} (N_t/N_0)$, where N_0 is the infectious MNV titer for untreated sample
204 and N_t is the infectious MNV titer for treated samples.

205

206 **2.11. Statistical analysis**

207 A statistical analysis of experimental data was performed using IBM SPSS Statistics
208 software (v.23) (IBM Corp., USA). Significant differences between homogeneous
209 sample groups were obtained through two-sided t-tests (means test of equality) at the
210 95% significance level ($p < 0.05$). For multiple comparisons, the p-values were adjusted
211 using the Bonferroni correction. This software was also used to carry out a Discriminant
212 Function Analysis (DFA) (cf. Section 3.2.3).


213

214 **3. Results and discussion**

215 **3.1. Impact of the molecular weight on the morphology of electrosprayed chitosan**

216 The use of electrospraying for the production of chitosan micro- and nanospheres for
217 drug delivery applications, and the influence of different processing parameters on the
218 obtained materials has already been reported for specific chitosans (Arya, Chakraborty,
219 Dube & Katti, 2009; Maeng, Choi, Kim & Kim, 2010; Pancholi, Ahras, Stride &
220 Edirisinghe, 2009; Yunoki, Tsuchiya, Fukui, Fujii & Maruyama, 2014; Zhang &

221 Kawakami, 2010). However, there is lack of information about the influence that the
222 molecular weight of chitosan itself has on the morphology of the materials obtained
223 through electrospraying. Thus, the formation of microencapsulation structures through
224 electrospinning/electrospraying using different chitosans with varying molecular
225 weights (Mw) and in a wide range of concentrations was evaluated under the same
226 processing conditions (i.e. an applied voltage of 17 kV, a flow rate of 0.15 mL/h and a
227 needle-collector distance of 10 cm), which were selected in preliminary trials so as to be
228 able to process all the solutions. The mean degree of deacetylation (DDA) of all
229 chitosans was 85% (± 2.5 %), and they were all dissolved in 90% acetic acid based on
230 previous works (Arya, Chakraborty, Dube & Katti, 2009; Pérez-Masiá, Lagaron &
231 Lopez-Rubio, 2015; Zhang & Kawakami, 2010). Figure 1 summarizes the types of
232 morphologies obtained for the different Mw-concentration pairs tested, showing the
233 micrographs obtained by SEM for some representative samples.



234
235 **Figure 1. Combined effect of molecular weight and concentration on the morphology of**
236 **electrospayed chitosan materials. White scale bars in all the SEM micrographs represent 2 μm.**

237 The results revealed that there was a small range of Mw-concentration conditions which
238 yielded neat electrospayed particles under the selected processing parameters. Small
239 deviations from these conditions either caused fiber formation or dripping of the
240 chitosan solutions. As expected, an increase in the molecular weight of chitosan caused
241 a decrease in the concentration at which it could be successfully electrospayed. Indeed,
242 as the molecular weight of a polymer increases, so does the frequency of chain
243 entanglements and thus the intermolecular cohesion in solution for a fixed
244 concentration. The formation of chain entanglements has been acknowledged as the
245 main factor determining the different morphologies which can be obtained when a
246 polymer solution is processed electrohydrodynamically (Shenoy, Bates, Frisch & Wnek,
247 2005). Accordingly, when a sufficient entanglement concentration is reached, jet
248 fragmentation during processing is prevented and fibers are formed (Gómez-

249 Mascaraque, Lagarón & López-Rubio, 2015). In a polymer solution, the number of
250 chain entanglements is affected both by the concentration and the molecular weight of
251 the polymer (Shenoy, Bates, Frisch & Wnek, 2005), and is related to the viscosity of
252 the solutions (Cross, 1970). Thus, in order to better understand the influence of the
253 molecular weight on the morphology of the processed materials, the rheological
254 behaviour of the chitosan solutions was examined, together with other solution
255 properties (surface tension and electrical conductivity) that are known to strongly
256 impact electrohydrodynamic processing (Pérez-Masiá, Lagaron & López-Rubio, 2014).


257

258 **3.2. Chitosan solution properties**

259 **3.2.1. Rheological behaviour**

260 In general, the most diluted chitosan solutions exhibited a Newtonian behavior, with a
261 linear relationship between the shear stress (σ) and the shear rate ($\dot{\gamma}$), regardless of the
262 molecular weight of the polymers. However, as the concentration increased, the
263 chitosan samples showed a shear thinning (pseudoplastic) behavior as previously
264 reported (Iversen, Kjøniksen, Nyström, Nakken, Palmgren & Tande, 1997), which was
265 manifested at lower concentrations for the higher molecular weight chitosans, and was
266 more evident as both the chitosan concentration and its molecular weight increased.
267 Figure S2 of the Supplementary Material shows the rheological profiles obtained for
268 different concentrations of chitosan with a molecular weight of 150 kDa, as a
269 representative example. In order to compare the viscosity of the different chitosan
270 solutions, its value at a constant high shear rate (200 s^{-1}) was plotted against the
271 polymer concentration for each molecular weight (cf. Figure 2). As predicted by Al-
272 Fariss and Al-Zahrani (1993) for diluted polymer solutions, the viscosity exponentially
273 increased with the concentration of chitosan at a constant temperature and shear rate,

274 while a potential relationship of the viscosity of chitosan solutions with its molecular
275 weight was observed (cf. Figure S3 of the Supplementary Material) as predicted by the
276 Mark–Houwink equation (Kasaai, 2007; Wang, Bo, Li & Qin, 1991). Overall, the
277 viscosity could be increased either by increasing the concentration or the mean
278 molecular weight of the polysaccharide, as expected. However, the values of the
279 viscosity alone did not explain the different morphologies obtained, as the ranges of this
280 parameter which yielded neat particles, particles with fibers or just dripping of the
281 solution overlapped (cf. Figure S4 of the Supplementary Material).



282
 283 Figure 2. Viscosity, surface tension and electrical conductivity of chitosan solutions as a function of
 284 the polymer concentration for different molecular weights.

285

286

287 **3.2.2. Surface tension and electrical conductivity**

288 The surface tension of the chitosan solutions hardly varied with the molecular weight or
289 the concentration of the polysaccharide, increasing only slightly as both increased (cf.
290 Figure 2). This lack of substantial variation with the concentration of biopolymer has
291 also been observed for other systems (Gómez-Mascaraque, Lagarón & López-Rubio,
292 2015).

293 The electrical conductivity initially increased with chitosan concentration for the
294 different molecular weights evaluated but eventually showed a maximum for the lower
295 Mw chitosans, i.e. for the solutions where the viscosity allowed evaluation of a wider
296 range of concentrations (cf. Figure 2). This can be explained taking into account that the
297 conductivity depends on both the concentration of charges and their mobility. As the
298 concentration of chitosan, and thus of protonated amino groups increased, the
299 conductivity augmented up to a point when the viscosity was so high that the mobility
300 of the charges was hampered. Indeed, these maximum was found at higher
301 concentrations for lower molecular weights. It was interesting to find that the
302 concentration at which each chitosan grade was successfully electrosprayed in the form
303 of neat particles had an electrical conductivity in the increasing slope of the curves,
304 before the maximum, because the viscosity at higher concentrations was too high and
305 gave rise to fibrils.

306 Anyhow, as expected, none of the solution properties could explain the differences in
307 the morphology of the obtained materials on its own. In contrast, a combination of them
308 could help predicting the sprayability of chitosan with a specific molecular weight at a
309 particular concentration.

310

3.2.3. Combined effect of the solution properties on the morphology




Figure 3. Electrospayed samples classified by their morphology as a function of the solution properties

312
313
314
315


316 Figure 3 shows the small region where the confluence of certain viscosity, surface
317 tension and electrical conductivity values yielded electrospayed particles free of
318 residual fibrils. In order to ascertain whether these three properties were effective in
319 predicting the morphology of the electrospayed materials, a Discriminant Function
320 Analysis (DFA) was conducted using the software IBM SPSS Statistics (v.23). This
321 type of statistical analysis is used to determine if a definite set of variables is successful
322 in predicting a category membership (Rencher, 1992). The DFA revealed that the three
323 variables were relevant to discriminate the different structures. The best rate of
324 discrimination was obtained using the combinations of the variables expressed in Eq.
325 (3) and (4) as standardized canonical discriminant functions, where γ is the surface

326 tension expressed in mN/m, κ is the electrical conductivity expressed in (mS/cm) and η
 327 is the viscosity expressed in Pa·s.

328 $Function\ 1 = -0.032 \cdot \gamma + 0.462 \cdot \kappa + 0.928 \cdot \log(\eta)$ Eq. (3)

329 $Function\ 2 = 1.365 \cdot \gamma + 0.0128 \cdot \kappa - 0.811 \cdot \log(\eta)$ Eq. (4)

330 With the above discriminant functions, the morphology obtained upon electro spraying
 331 of chitosan solutions could be correctly predicted for 84.2% of the assayed solutions (cf.
 332 Figure 4). Moreover, all solutions leading to neat particles were correctly classified.



333

334 **Figure 4. Group graphs obtained from the discriminant functions (Eq. (3) and (4)) and**
 335 **classification results**


336

337 From the different molecular weight – concentration combinations which gave rise to
338 fiber-free electrosprayed particles, the chitosan with the lowest assayed molecular
339 weight was selected, as it allowed the highest electrosprayable concentration and thus
340 the greatest productivity. Thus, the chitosan of 25 kDa at 5% (w/v) concentration was
341 selected for further analysis.

342

343 **3.3. Effect of acetic acid concentration**

344 One of the solution parameters that are crucial for the electrohydrodynamic processing
345 of chitosan solutions is the concentration of the acetic acid solution used as solvent.
346 While Homayoni, Ravandi and Valizadeh (2009) stated that the acetic acid
347 concentration should be in the range of 70-90% for optimal electrospinning to obtain
348 nanofibers, Arya, Chakraborty, Dube and Katti (2009) concluded that the optimum
349 concentration for successful electrospraying was 90%, though that might only apply for
350 the particular chitosan they used. This concentration has been selected in other works to
351 produce electrosprayed particles from chitosan (Pérez-Masiá, Lagaron & Lopez-Rubio,
352 2015; Sun et al., 2015) without further evaluation. However, Zhang and Kawakami
353 (2010) extended the range of sprayability (again, for a particular chitosan of high
354 molecular weight) down to a 50%, noting that decreasing the acetic acid concentration
355 caused a reduction in the mean particle size. Due to the variability of data found in the
356 literature in this respect, the concentration of acetic acid was optimized for our
357 particular system (chitosan 25 kDa, 5% w/v).




358
359 **Figure 5. Morphology of electro sprayed chitosan (25 kDa, 5% w/v) obtained from different acetic**
360 **acid concentrations (90-20% v/v). White scale bars in all the SEM micrographs represent 2 μ m.**

361

362 Figure 5 shows the impact of the acetic acid concentration on the morphology of the
363 electro sprayed chitosan. It could be observed that concentrations below 80% yielded
364 particle aggregates and even dripping of the solution for a 20% acetic acid. As the
365 surface tension of the solutions did not vary significantly with the acetic acid
366 concentration (cf. Figure S5 of the Supplementary Material), this dripping could be
367 attributed to a slight decrease in the viscosity of the solutions in combination with a
368 sharp increase in their electrical conductivity at low acetic concentrations, which had
369 already been observed by Zhang and Kawakami (2010) and ascribed to the higher
370 degree of dissociation of the acid at low concentrations. However, a concentration of
371 80% gave rise to more spherical particles with more homogeneous sizes than the 90%
372 used in the previous sections. Having both concentrations the same conductivity, this
373 was attributed to the maximum of viscosity observed at 80% acetic acid (cf. Figure S5
374 of the Supplementary Material), also patent in the cited work (Zhang & Kawakami,
375 2010) although not commented. Therefore, an optimum acetic acid concentration of
376 80% was selected to produce our delivery system.

378 3.4. Morphological and chemical characterization of EGCG-loaded capsules

379 The conditions selected in the previous section for the production of electrospayed
380 chitosan delivery vehicles were used to produce EGCG-loaded chitosan particles with
381 a theoretical EGCG content of 10% w/w of the capsules. Figure 6(a) shows a
382 micrograph of the obtained material, which exhibits a similar morphology as that
383 obtained in the absence of the bioactive compound, although slightly less homogeneous
384 in size.



386 **Figure 6. Morphology of EGCG-loaded electrosprayed chitosan particles (a) and infrared spectra**
387 **of unloaded and EGCG-loaded electrosprayed chitosan particles (b). The white scale bar in the**
388 **SEM micrograph represents 2 μm .**

389

390 The effective incorporation of EGCG within the chitosan particles was evidenced by the
391 presence of its characteristic infrared absorption band centred at 1221 cm^{-1} (cf. Figure
392 6(b)), as observed for EGCG-loaded spray-dried chitosan particles obtained in a
393 previous work (Gómez-Mascaraque, Soler & López-Rubio, 2016). This band was
394 slightly displaced in the capsules with respect to free EGCG, being centred at 1223 cm^{-1}
395 in the latter (spectrum showed elsewhere (Gómez-Mascaraque, Lagarón & López-
396 Rubio, 2015)). Other spectral bands of chitosan were also modified. Specifically, the
397 Amide I band shifted from 1634 cm^{-1} in the unloaded particles to 1629 cm^{-1} in the
398 EGCG-loaded capsules. These changes suggested the presence of intermolecular
399 interactions between the bioactive molecule and its biopolymeric vehicle, which might
400 contribute to the stabilization of the former as previously suggested (Gómez-
401 Mascaraque, Lagarón & López-Rubio, 2015).

402

403 **3.5. Antioxidant activity and encapsulation efficiency**

404 The ABTS radical cation decolourization assay (Re, Pellegrini, Proteggente, Pannala,
405 Yang & Rice-Evans, 1999) was used to compare the antioxidant activity of free and
406 encapsulated EGCG, and to indirectly estimate the encapsulation efficiency of the
407 system. Therefore, the radical scavenging activities (RSA) of solutions of commercial
408 EGCG (0.15 mg/mL) and encapsulated EGCG (theoretical concentration of 0.15
409 mg/mL) in acetic acid 20% v/v, as well as solutions of the unloaded chitosan particles
410 (same concentration as for the loaded ones) were calculated using Eq. (1). Solvent
411 blanks were run too.

412 The results showed no significant differences ($p < 0.05$) between the RSA of the
413 unloaded chitosan particles ($2.3\% \pm 0.3\%$) and that of the solvent blank ($2.2\% \pm 0.4\%$),
414 suggesting that the polysaccharide exerted no significant antioxidant activity at the
415 assayed concentration. Hence, the potential contribution of the encapsulating matrix to
416 the total antioxidant activity of the EGCG-loaded capsules was neglected. The
417 antioxidant activity of encapsulated EGCG (RSA = $23.0\% \pm 0.7\%$) was somewhat
418 lower than that of free EGCG (RSA = $28.9\% \pm 1.7\%$) at the same theoretical
419 concentration, implying some bioactivity loss during encapsulation.

420 From these results, the encapsulation efficiency defined by Eq. (2) was estimated to be
421 $79.6\% \pm 2.4\%$. This considerably high value was consistent with similar encapsulation
422 systems based on chitosan used as delivery vehicles for EGCG (Gómez-Mascaraque,
423 Soler & López-Rubio, 2016).

424

425 **3.6. Antiviral activity**

426 Table 1 summarizes the results obtained from the antiviral activity assays performed on
427 murine norovirus. While a concentration of 0.25 mg/mL of EGCG was insufficient to
428 observe a significant reduction in the recovered titer of the virus after 2 h of incubation,
429 a concentration of 2.5 mg/mL of the polyphenol did cause a significant reduction, which
430 was statistically lower for the encapsulated compound suggesting that 2 h was
431 insufficient for the complete release of the bioactive. On the contrary, when the viruses
432 were exposed to EGCG overnight, the recovered titer was lower than 1.15 TCID₅₀/mL
433 for both free and encapsulated EGCG at 2.5 mg/mL and, more interestingly, the
434 reduction was significantly higher for the encapsulated than for the free flavonoid at
435 0.25 mg/mL.

436

437

Table 1. Antiviral activity of free and encapsulated EGCG against murine norovirus

	[Sample] (mg/mL)	Theoretical [EGCG] (mg/mL)	2 h		Overnight	
			Recovered titer (TCID ₅₀ /mL)	Reduction	Recovered titer (TCID ₅₀ /mL)	Reduction
PBS	-		6.45 ± 0.35 ^A	-	5.87 ± 0.38 ^A	-
Free EGCG	2.5	2.5	4.13 ± 0.10 ^B	2.32	<1.15 ^B	>4.72
EGCG- loaded	0.25	0.25	6.03 ± 0.12 ^A	0.42	4.71 ± 0.12 ^C	1.16
chitosan	25	2.5	5.20 ± 0.00 ^C	1.25	<1.15 ^B	>4.72
	2.5	0.25	6.07 ± 0.21 ^A	0.38	3.48 ± 0.38 ^D	2.39

438 * Within each column, different letters (A, B, C and D) denote significant differences between
439 treatments (p < 0.05).

440

441 Given that the unloaded electrosprayed chitosan did not show antiviral activity (data not
442 shown), these results can be explained considering that the bioactive compound might
443 have been gradually released from the microcapsules. In fact, a sustained release of
444 bioactives is often desirable and pursued through their encapsulation (Singh, 2010). In
445 our system, the lower antiviral activity of encapsulated EGCG at short exposure times
446 and its substantial increase at longer time periods suggested a gradual release of the
447 active compound from the chitosan capsules, mainly ascribed to a Fickian diffusion
448 mechanism with some contribution from polymer relaxation phenomena. This result is
449 consistent with the release profiles obtained for similar systems based on EGCG-loaded
450 chitosan microcapsules (Gómez-Mascaraque, Soler & López-Rubio, 2016). On the
451 other hand, the fact that the reduction in the recovered titer was higher for the
452 encapsulated EGCG after an overnight incubation implied that free EGCG was less
453 active against the MNV than the EGCG released from the capsules. As the assay was

454 carried out in PBS at 37°C to mimic physiological conditions, this can be easily
455 explained by the great instability of EGCG in slightly alkaline solutions (Sang, Lee,
456 Hou, Ho & Yang, 2005; Su, Leung, Huang & Chen, 2003; Wang, Zhou & Wen, 2006).
457 Therefore, the results suggested that while free EGCG degraded with time in PBS,
458 microencapsulation of the compound within the electrosprayed chitosan particles
459 delayed its degradation, hence protecting its antiviral activity in simulated physiological
460 conditions.

461

462 **4. Conclusions**

463 There was a small range of molecular weight – concentration combinations which gave
464 rise to electrosprayed particles without leading to solution dripping or fiber formation.
465 Both parameters caused a considerable increase in the viscosity of the solutions,
466 although the values of the viscosity on their own were not enough to predict whether a
467 particular chitosan solution would lead to fiber-free particles. A Discriminant Function
468 Analysis revealed that the surface tension and the electrical conductivity of the solutions
469 were also relevant properties in predicting the obtained morphologies. The analysis
470 allowed the accurate prediction of 84.2% of the electrosprayed chitosan solutions. The
471 chitosan with the lowest assayed molecular weight (25 kDa), which allowed the highest
472 electrosprayable concentration (5% w/v) and thus the highest productivity, was used to
473 produce EGCG-loaded encapsulation structures achieving an encapsulation efficiency
474 close to 80%. Microencapsulated EGCG showed prolonged antiviral activity against
475 murine norovirus as compared to the free compound, suggesting that EGCG was
476 gradually released from the chitosan capsules and that the encapsulation matrix exerted

477 a protective effective on the active compound against degradation in simulated
478 physiological conditions.

479

480 **Acknowledgements**

481 Laura G. Gómez-Mascaraque is recipient of a predoctoral contract from the Spanish
482 Ministry of Economy and Competitiveness (MINECO), Call 2013. Gloria Sanchez was
483 supported by the “Ramón y Cajal” Young Investigator Program. The authors would like
484 to thank the Spanish MINECO project AGL2015-63855-C2-1 and INIA grant
485 RTA2014-00024-C04-03 for financial support. Authors would also like to thank the
486 Central Support Service for Experimental Research (SCSIE) of the University of
487 Valencia for the electronic microscopy service.

488

489 **References**

- 490 Al-Fariss, T., & Al-Zahrani, S. (1993). Rheological behaviour of some dilute polymer solutions.
491 *Engineering Sciences*, 5(1).
- 492 Anitha, A., Sowmya, S., Kumar, P. T. S., Deepthi, S., Chennazhi, K. P., Ehrlich, H., Tsurkan, M., &
493 Jayakumar, R. (2014). Chitin and chitosan in selected biomedical applications. *Progress in*
494 *Polymer Science*, 39(9), 1644-1667.
- 495 Anu Bhushani, J., & Anandharamakrishnan, C. (2014). Electrospinning and electrospraying
496 techniques: Potential food based applications. *Trends in Food Science & Technology*, 38(1), 21-
497 33.
- 498 Anumansirikul, N. (2007). *Chitosan-nanoparticles as UV filter and carrier for cosmetic actives*
499 *2007 NSTI Nanotechnology Conference and Trade Show - NSTI Nanotech 2007, Technical*
500 *Proceedings*.
- 501 Arya, N., Chakraborty, S., Dube, N., & Katti, D. S. (2009). Electrospinning: A facile technique for
502 synthesis of chitosan-based micro/nanospheres for drug delivery applications. *Journal of*
503 *Biomedical Materials Research Part B: Applied Biomaterials*, 88B(1), 17-31.
- 504 Badwan, A., Rashid, I., Omari, M., & Darras, F. (2015). Chitin and Chitosan as Direct
505 Compression Excipients in Pharmaceutical Applications. *Marine drugs*, 13(3), 1519-1547.
- 506 Barras, A., Mezzetti, A., Richard, A., Lazzaroni, S., Roux, S., Melnyk, P., Betbeder, D., &
507 Monfilliette-Dupont, N. (2009). Formulation and characterization of polyphenol-loaded lipid
508 nanocapsules. *International Journal of Pharmaceutics*, 379(2), 270-277.
- 509 Bock, N., Dargaville, T. R., & Woodruff, M. A. (2012). Electrospinning of polymers with
510 therapeutic molecules: State of the art. *Progress in Polymer Science*, 37(11), 1510-1551.

511 Cross, M. M. (1970). Viscosity, molecular weight and chain entanglement. *Polymer*, 11(5), 238-
512 244.

513 Chakraborty, S., Liao, I. C., Adler, A., & Leong, K. W. (2009). Electrohydrodynamics: A facile
514 technique to fabricate drug delivery systems. *Advanced Drug Delivery Reviews*, 61(12), 1043-
515 1054.

516 Cheung, R. C. F., Ng, T., Wong, J., & Chan, W. (2015). Chitosan: An Update on Potential
517 Biomedical and Pharmaceutical Applications. *Marine drugs*, 13(8), 5156-5186.

518 Dhiman, R. K. (2011). The Green Tea Polyphenol, Epigallocatechin-3-Gallate (EGCG)—One Step
519 Forward in Antiviral Therapy Against Hepatitis C Virus. *Journal of Clinical and Experimental*
520 *Hepatology*, 1(3), 159-160.

521 Elizaquível, P., Azizkhani, M., Aznar, R., & Sánchez, G. (2013). The effect of essential oils on
522 norovirus surrogates. *Food Control*, 32(1), 275-278.

523 Estevinho, B., Rocha, F., Santos, L., & Alves, A. (2013). Microencapsulation with chitosan by
524 spray drying for industry applications – A review. *Trends in Food Science & Technology*, 31(2),
525 138-155.

526 Fathi, M., Martin, A., & McClements, D. J. (2014). Nanoencapsulation of food ingredients using
527 carbohydrate based delivery systems. *Trends in Food Science & Technology*, 39(1), 18-39.

528 Fu, N., Zhou, Z., Jones, T. B., Tan, T. T., Wu, W. D., Lin, S. X., Chen, X. D., & Chan, P. P. (2011).
529 Production of monodisperse epigallocatechin gallate (EGCG) microparticles by spray drying for
530 high antioxidant activity retention. *International Journal of Pharmaceutics*, 413(1-2), 155-166.

531 Geng, X., Kwon, O.-H., & Jang, J. (2005). Electrospinning of chitosan dissolved in concentrated
532 acetic acid solution. *Biomaterials*, 26(27), 5427-5432.

533 Ghorani, B., & Tucker, N. (2015). Fundamentals of electrospinning as a novel delivery vehicle
534 for bioactive compounds in food nanotechnology. *Food Hydrocolloids*, 51, 227-240.

535 Gómez-Mascaraque, L. G., Lagarón, J. M., & López-Rubio, A. (2015). Electrospayed gelatin
536 submicroparticles as edible carriers for the encapsulation of polyphenols of interest in
537 functional foods. *Food Hydrocolloids*, 49(0), 42-52.

538 Gómez-Mascaraque, L. G., & López-Rubio, A. (2016). Protein-based emulsion electrospayed
539 micro- and submicroparticles for the encapsulation and stabilization of thermosensitive
540 hydrophobic bioactives. *Journal of Colloid and Interface Science*, 465, 259-270.

541 Gómez-Mascaraque, L. G., Soler, C., & López-Rubio, A. (2016). Stability and bioaccessibility of
542 flavonoids within edible micro-hydrogels. Chitosan vs. gelatin, a comparative study. *Food*
543 *Hydrocolloids*, *In press*.

544 Homayoni, H., Ravandi, S. A. H., & Valizadeh, M. (2009). Electrospinning of chitosan nanofibers:
545 Processing optimization. *Carbohydrate Polymers*, 77(3), 656-661.

546 Ishihara, M. (2015). A review on biomedical applications of chitosan-based biomaterials.
547 *International Journal of Pharma and Bio Sciences*, 6(3), P162-P178.

548 Iversen, C., Kjøniksen, A.-L., Nyström, B., Nakken, T., Palmgren, O., & Tande, T. (1997). Linear
549 and nonlinear rheological responses in aqueous systems of hydrophobically modified chitosan
550 and its unmodified analogue. *Polymer Bulletin*, 39(6), 747-754.

551 Jaworek, A., & Sobczyk, A. T. (2008). Electrospaying route to nanotechnology: An overview.
552 *Journal of Electrostatics*, 66(3–4), 197-219.

553 Jiménez-Martín, E., Gharsallaoui, A., Pérez-Palacios, T., Carrascal, J., & Rojas, T. (2014).
554 Suitability of using monolayered and multilayered emulsions for microencapsulation of ω -3
555 fatty acids by spray drying: Effect of storage at different temperatures. *Food and Bioprocess*
556 *Technology*, 8(1), 100-111.

557 Jimtaisong, A., & Saewan, N. (2014). Utilization of carboxymethyl chitosan in cosmetics.
558 *International journal of cosmetic science*, 36(1), 12-21.

559 Kasaai, M. R. (2007). Calculation of Mark–Houwink–Sakurada (MHS) equation viscometric
560 constants for chitosan in any solvent–temperature system using experimental reported
561 viscometric constants data. *Carbohydrate Polymers*, 68(3), 477-488.

562 Khor, E., & Lim, L. Y. (2003). Implantable applications of chitin and chitosan. *Biomaterials*,
563 24(13), 2339-2349.

564 Larsen, C. A., & Dashwood, R. H. (2009). Suppression of Met activation in human colon cancer
565 cells treated with (-)-epigallocatechin-3-gallate: Minor role of hydrogen peroxide. *Biochemical*
566 *and Biophysical Research Communications*, 389(3), 527-530.

567 Larsen, C. A., & Dashwood, R. H. (2010). (-)-Epigallocatechin-3-gallate inhibits Met signaling,
568 proliferation, and invasiveness in human colon cancer cells. *Archives of Biochemistry and*
569 *Biophysics*, 501(1), 52-57.

570 López-Rubio, A., & Lagaron, J. M. (2012). Whey protein capsules obtained through
571 electrospaying for the encapsulation of bioactives. *Innovative Food Science & Emerging*
572 *Technologies*, 13(0), 200-206.

573 Luo, Y., & Wang, Q. Recent Advances of Chitosan and Its Derivatives for Novel Applications in
574 Food Science. *J Food Processing & Beverages*, 1(1), 13.

575 Maeng, Y.-J., Choi, S.-W., Kim, H. O., & Kim, J.-H. (2010). Culture of human mesenchymal stem
576 cells using electrosprayed porous chitosan microbeads. *Journal of Biomedical Materials*
577 *Research Part A*, 92A(3), 869-876.

578 Pancholi, K., Ahras, N., Stride, E., & Edirisinghe, M. (2009). Novel electrohydrodynamic
579 preparation of porous chitosan particles for drug delivery. *Journal of Materials Science:*
580 *Materials in Medicine*, 20(4), 917-923.

581 Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010). Targeted delivery of low molecular
582 drugs using chitosan and its derivatives. *Advanced Drug Delivery Reviews*, 62(1), 28-41.

583 Pérez-Masiá, R., Lagaron, J., & Lopez-Rubio, A. (2015). Morphology and Stability of Edible
584 Lycopene-Containing Micro- and Nanocapsules Produced Through Electrospaying and Spray
585 Drying. *Food and Bioprocess Technology*, 8(2), 459-470.

586 Pérez-Masiá, R., Lagaron, J., & López-Rubio, A. (2014). Development and Optimization of Novel
587 Encapsulation Structures of Interest in Functional Foods Through Electrospaying. *Food and*
588 *Bioprocess Technology*, 7(11), 3236-3245.

589 Pérez-Masiá, R., López-Nicolás, R., Periago, M. J., Ros, G., Lagaron, J. M., & López-Rubio, A.
590 (2015). Encapsulation of folic acid in food hydrocolloids through nanospray drying and
591 electrospaying for nutraceutical applications. *Food Chemistry*, 168, 124-133.

592 Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., & Rice-Evans, C. (1999).
593 Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free*
594 *Radical Biology and Medicine*, 26(9-10), 1231-1237.

595 Rencher, A. C. (1992). Interpretation of Canonical Discriminant Functions, Canonical Variates,
596 and Principal Components. *The American Statistician*, 46(3), 217-225.

597 Ribeiro, M. P., Espiga, A., Silva, D., Baptista, P., Henriques, J., Ferreira, C., Silva, J. C., Borges, J.
598 P., Pires, E., Chaves, P., & Correia, I. J. (2009). Development of a new chitosan hydrogel for
599 wound dressing. *Wound Repair and Regeneration*, 17(6), 817-824.

600 Sang, S., Lee, M.-J., Hou, Z., Ho, C.-T., & Yang, C. S. (2005). Stability of Tea Polyphenol (-)-
601 Epigallocatechin-3-gallate and Formation of Dimers and Epimers under Common Experimental
602 Conditions. *Journal of Agricultural and Food Chemistry*, 53(24), 9478-9484.

603 Shenoy, S. L., Bates, W. D., Frisch, H. L., & Wnek, G. E. (2005). Role of chain entanglements on
604 fiber formation during electrospinning of polymer solutions: good solvent, non-specific
605 polymer-polymer interaction limit. *Polymer*, 46(10), 3372-3384.

606 Singh, B. N., Shankar, S., & Srivastava, R. K. (2011). Green tea catechin, epigallocatechin-3-
607 gallate (EGCG): Mechanisms, perspectives and clinical applications. *Biochemical Pharmacology*,
608 82(12), 1807-1821.

609 Singh, M. N. (2010). Microencapsulation: A promising technique for controlled drug delivery.
610 *Research in Pharmaceutical Sciences*, 5(2), 65-77.

611 Singh, R., Akhtar, N., & Haqqi, T. M. (2010). Green tea polyphenol epigallocatechi3-gallate:
612 Inflammation and arthritis. *Life Sciences*, 86(25-26), 907-918.

613 Sosnik, A. (2014). Production of drug-loaded polymeric nanoparticles by electrospraying
614 technology. *Journal of biomedical nanotechnology*, 10(9), 2200-2217.

615 Steinmann, J., Buer, J., Pietschmann, T., & Steinmann, E. (2013). Anti-infective properties of
616 epigallocatechin-3-gallate (EGCG), a component of green tea. *British journal of pharmacology*,
617 168(5), 1059-1073.

618 Su, Y. L., Leung, L. K., Huang, Y., & Chen, Z. Y. (2003). Stability of tea theaflavins and catechins.
619 *Food Chemistry*, 83(2), 189-195.

620 Sun, K., & Li, Z. H. Preparations, properties and applications of chitosan based nanofibers
621 fabricated by electrospinning. *Express Polymer Letters*, 5(4), 342-361.

622 Sun, N., Wang, J., Ji, L., Hong, S., Dong, J., Guo, Y., Zhang, K., & Pei, R. (2015). A Cellular
623 Compatible Chitosan Nanoparticle Surface for Isolation and In Situ Culture of Rare Number
624 CTCs. *Small*, 11(40), 5444-5451.

625 Tapia-Hernández, J. A., Torres-Chavez, P. I., Ramirez-Wong, B., Rascon-Chu, A., Plascencia-
626 Jatomea, M., Barreras-Urbina, C. G., Rangel-Vázquez, N. A., & Rodríguez-Felix, F. (2015). Micro-
627 and Nano-Particles by Electrospray: Advances and Applications in Foods. *Journal of Agricultural
628 and Food Chemistry*.

629 Varshosaz, J. (2007). The promise of chitosan microspheres in drug delivery systems.

630 Wang, R., Zhou, W., & Wen, R.-a. H. (2006). Kinetic study of the thermal stability of tea
631 catechins in aqueous systems using a microwave reactor. *Journal of Agricultural and Food
632 Chemistry*, 54(16), 5924-5932.

633 Wang, W., Bo, S., Li, S., & Qin, W. (1991). Determination of the Mark-Houwink equation for
634 chitosans with different degrees of deacetylation. *International Journal of Biological
635 Macromolecules*, 13(5), 281-285.

636 Wang, X.-X., Ju, X.-J., Sun, S.-X., Xie, R., Wang, W., Liu, Z., & Chu, L.-Y. (2015). Monodisperse
637 erythrocyte-sized and acid-soluble chitosan microspheres prepared via electrospraying. *RSC
638 Advances*, 5(43), 34243-34250.

639 Xiao, X. (2008). Antiviral effect of epigallocatechin gallate (EGCG) on influenza A virus. *China
640 journal of Chinese materia medica*, 33(22), 2678-2682.

641 Yunoki, A., Tsuchiya, E., Fukui, Y., Fujii, A., & Maruyama, T. (2014). Preparation of
642 Inorganic/Organic Polymer Hybrid Microcapsules with High Encapsulation Efficiency by an
643 Electrospray Technique. *ACS applied materials & interfaces*, 6(15), 11973-11979.

644 Zaki, N. (2014). Progress and Problems in Nutraceuticals Delivery. *J Bioequiv Availab*, 6, 075-
645 077.

646 Zamani, M., Prabhakaran, M. P., & Ramakrishna, S. (2013). Advances in drug delivery via
647 electrospun and electrosprayed nanomaterials. *International journal of nanomedicine*, 8, 2997.

648 Zhang, S., & Kawakami, K. (2010). One-step preparation of chitosan solid nanoparticles by
649 electrospray deposition. *International Journal of Pharmaceutics*, 397(1-2), 211-217.

650 Zivanovic, S., Davis, R., & Golden, D. (2014). Chitosan as an antimicrobial in food products.
651 *Handbook of Natural Antimicrobials for Food Safety and Quality*, 153.

652


653

654 **Highlights**

- 655 • Mw – concentration combinations for stable chitosan electro spraying are limited
- 656 • Viscosity, surface tension and conductivity help predicting morphology of
657 materials
- 658 • EGCG microencapsulated in selected electro sprayed chitosan with 80%
659 efficiency
- 660 • Encapsulation prolonged antiviral activity of EGCG against MNV

661

662 Supplementary Material




663

664


Figure S1. Schematic chemical structure of chitosan.

665



666


667 **Figure S2.** Rheological profiles (shear stress and viscosity vs. shear rate) for solutions
668 of the chitosan with a Mw of 150 kDa in 90% acetic acid and different concentrations
669 (1-4% w/v).



670

671 **Figure S3.** Viscosity of chitosan solutions as a function of the mean molecular weight
672 for different concentrations.

673




674

675 **Figure S4.** Experimental values of the viscosity (at 200 s^{-1}) of chitosan solutions giving

676

rise to each of the obtained morphologies.



677

678 **Figure S5.** Viscosity, surface tension and electrical conductivity of chitosan solutions
679 (25 kDa, 5% w/v) as a function of the acetic acid concentration in the solvent.

680

681